# Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00662805** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 762 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Salmeterol/Fluticasone propionate

## Key facts

- **NCT ID:** NCT00662805
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 762 (ACTUAL)
- **Last updated:** 2014-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00662805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00662805, "Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00662805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*